Page last updated: 2024-09-04

carbapenems and Communicable Diseases

carbapenems has been researched along with Communicable Diseases in 25 studies

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (4.00)18.2507
2000's0 (0.00)29.6817
2010's9 (36.00)24.3611
2020's15 (60.00)2.80

Authors

AuthorsStudies
Akova, M; Bassetti, M; Bitterman, R; Bonomo, RA; Carrara, E; Daikos, GL; de Waele, J; Gandra, S; Garnacho-Montero, J; Harbarth, S; Lindemann, PC; Mouton, JW; Paul, M; Pulcini, C; Retamar, P; Rodríguez-Baño, J; Seme, K; Tacconelli, E; Tängdén, T; Tumbarello, M; Yu, Y1
Arnold, SLM; Baker, S; Ballell Pages, L; Castañeda, P; Cortés, A; Dayao, D; de Cozar, C; de Mercado, J; Fernández Álvaro, E; García-Perez, A; Ha Thanh, T; Martínez-Martínez, MS; Martinot, A; McCloskey, M; Pavlinac, P; Price, A; Shaheen, S; Singa, B; Tran Do Hoang, N; Tzipori, S; Urones, B; Voong Vinh, P; Walson, J; Willé, DR1
Apisarnthanarak, A; Jantarathaneewat, K; Montakantikul, P; Nanthapisal, S; Rutjanawech, S; Weber, DJ1
Aitken, SL; Bonomo, RA; Clancy, CJ; Mathers, AJ; Tamma, PD; van Duin, D3
Aguado, JM; Fernández-Ruiz, M; Gutiérrez-Gutiérrez, B; Martínez-Martínez, L; Pascual, Á; Pérez-Nadales, E; Rodríguez-Baño, J; Torre-Cisneros, J1
Bae, S; Chang, HH; Cheong, HS; Heo, ST; Hur, J; Hwang, S; Jung, DS; Kim, B; Kim, J; Kim, SW; Kim, Y; Kwon, KT; Lee, MS; Lee, S; Moon, C; Sohn, KM; Wi, YM; Yoon, YK1
Fang, Q; Feng, Y; Hu, Y; McNally, A; Wang, C; Yang, Y; Zhao, F; Zong, Z1
Cantón, R; Ruiz-Garbajosa, P1
Duan, X; Li, S; Peng, Y; Rui, Y1
Badia, X; Cantón, R; González, J; Huarte, R; Morata, L; Muñoz, R; Tort, M; Trillo-Mata, JL1
Bryan, A; Bryson-Cahn, C; Chan, JD; Jain, R; Kim, HN; Krantz, EM; Lan, KF; Liu, C; Lynch, JB; Mani, NS; Pottinger, PS1
Furuno, Y; Kanatani, N; Koga, H; Matono, T; Nakamura, K; Uchida, M; Umeda, Y; Yamashita, T1
Bini, T; Cona, A; d'Arminio Monforte, A; Gazzola, L; Marchetti, GC; Viganò, O1
Bian, X; Feng, M; Li, X; Liu, X; Song, S; Zhang, J; Zhang, X; Zheng, H1
Ang, BS; Ling, LM; Lye, DC; Ng, TM; Phang, VY; Tan, MW; Tan, SH; Tay, HL; Teng, CB; Young, B1
Al Zaibag, M; Aljohany, SM; Alothman, AF; Arabi, YM; Baharoon, S; Balkhy, HH; El-Metwally, A; El-Saed, A1
Alp, E; Alves, J; Conway-Morris, A; Kalwaje Eshwara, V; Lagunes, L; Mer, M; Rello, J; Zhang, Z1
Bodmann, KF1
About, F; Berdougo, B; Brun-Buisson, C; De Pontfarcy, A; Delory, T; Emirian, A; Lesprit, P1
Bi, J; Chen, X; Li, Y; Peng, Y; Shi, J; Yao, Z; Ye, X1
Heist, BS; Higuchi, M; Honda, H; Horiuchi, M; Tagashira, Y; Tokuda, Y1
Goodlet, KJ; Nailor, MD1
Holbrook, KA; Lowy, FD1

Reviews

5 review(s) available for carbapenems and Communicable Diseases

ArticleYear
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:4

    Topics: Anti-Bacterial Agents; Carbapenems; Communicable Diseases; Critical Care; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans

2022
Extended-spectrum β-lactamase-producing and carbapenem-resistant Enterobacterales bloodstream infection after solid organ transplantation: Recent trends in epidemiology and therapeutic approaches.
    Transplant infectious disease : an official journal of the Transplantation Society, 2022, Volume: 24, Issue:4

    Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Communicable Diseases; Gram-Negative Bacteria; Humans; Organ Transplantation; Sepsis

2022
Prevalence and clonal diversity of carbapenem-resistant Klebsiella pneumoniae causing neonatal infections: A systematic review of 128 articles across 30 countries.
    PLoS medicine, 2023, Volume: 20, Issue:6

    Topics: Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Communicable Diseases; Humans; Infant, Newborn; Klebsiella Infections; Klebsiella pneumoniae; Prevalence

2023
Treatment guidelines for multidrug-resistant Gram-negative microorganisms.
    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2023, Volume: 36 Suppl 1

    Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cephalosporins; Communicable Diseases; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests

2023
Beta-lactam antibiotics.
    Cancer investigation, 1998, Volume: 16, Issue:6

    Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Cephalosporins; Communicable Diseases; Humans; Penicillins

1998

Other Studies

20 other study(ies) available for carbapenems and Communicable Diseases

ArticleYear
The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant
    eLife, 2022, 03-15, Volume: 11

    Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Child; Communicable Diseases; Diarrhea; Drug Repositioning; Humans; Mice; Shigella; Swine

2022
Impact of an infectious diseases pharmacist-led intervention on antimicrobial stewardship program guideline adherence at a Thai medical center.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2022, 07-22, Volume: 79, Issue:15

    Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Communicable Diseases; Guideline Adherence; Hospitals; Humans; Pharmacists; Thailand

2022
Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 08-25, Volume: 75, Issue:2

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Cephalosporins; Child; Communicable Diseases; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; United States

2022
Use of Antibiotics Within the Last 14 Days of Life in Korean Patients: A Nationwide Study.
    Journal of Korean medical science, 2023, Mar-06, Volume: 38, Issue:9

    Topics: Anti-Bacterial Agents; Carbapenems; Communicable Diseases; Humans; Republic of Korea; Retrospective Studies

2023
Molecular characteristics of carbapenem-resistant Acinetobacter spp. from clinical infection samples and fecal survey samples in Southern China.
    BMC infectious diseases, 2019, Oct-28, Volume: 19, Issue:1

    Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; China; Colistin; Communicable Diseases; Drug Resistance, Bacterial; Feces; Genetic Variation; Genotype; Humans; Integrons; Microbial Sensitivity Tests; Polymerase Chain Reaction; Sequence Analysis, DNA

2019
Determining the burden of infectious diseases caused by carbapenem-resistant gram-negative bacteria in Spain.
    Enfermedades infecciosas y microbiologia clinica (English ed.), 2021, Volume: 39, Issue:4

    Topics: Anti-Bacterial Agents; Carbapenems; Communicable Diseases; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Spain

2021
Postprescription Review With Threat of Infectious Disease Consultation and Sustained Reduction in Meropenem Use Over Four Years.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 12-06, Volume: 73, Issue:11

    Topics: Anti-Bacterial Agents; Carbapenems; Communicable Diseases; Humans; Meropenem; Referral and Consultation; Retrospective Studies

2021
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aerug
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 04-08, Volume: 72, Issue:7

    Topics: Adult; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Child; Communicable Diseases; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa

2021
Impact of an infectious disease physician-led carbapenem postprescription feedback on prescribing behavior in a Japanese tertiary hospital: A before-after study.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2021, Volume: 27, Issue:3

    Topics: Anti-Bacterial Agents; Carbapenems; Communicable Diseases; Controlled Before-After Studies; Feedback; Humans; Japan; Physicians; Tertiary Care Centers

2021
Impact of daily versus weekly service of infectious diseases consultation on hospital antimicrobial consumption: a retrospective study.
    BMC infectious diseases, 2020, Nov-07, Volume: 20, Issue:1

    Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Communicable Diseases; Drug Resistance, Multiple, Bacterial; Female; Follow-Up Studies; Glycopeptides; Hospitals; Humans; Italy; Male; Middle Aged; Referral and Consultation; Retrospective Studies; Treatment Outcome

2020
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aerug
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 04-08, Volume: 72, Issue:7

    Topics: Adult; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Child; Communicable Diseases; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa

2021
Epidemiological and genomic characteristics of Acinetobacter baumannii from different infection sites using comparative genomics.
    BMC genomics, 2021, Jul-12, Volume: 22, Issue:1

    Topics: Acinetobacter baumannii; Acinetobacter Infections; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; China; Communicable Diseases; Drug Resistance, Multiple, Bacterial; Genomics; Humans; Microbial Sensitivity Tests; Phylogeny

2021
Clinical impact of non-antibiotic recommendations by a multi-disciplinary antimicrobial stewardship team.
    International journal of antimicrobial agents, 2017, Volume: 50, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Communicable Diseases; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Retrospective Studies; Survival Analysis; Treatment Outcome; Young Adult

2017
Antimicrobial consumption in five adult intensive care units: a 33-month surveillance study.
    Antimicrobial resistance and infection control, 2018, Volume: 7

    Topics: Adult; Anti-Bacterial Agents; Antimicrobial Stewardship; Carbapenems; Colistin; Communicable Diseases; Cost-Benefit Analysis; Drug Utilization; Female; Humans; Intensive Care Units; Male; Meropenem; Middle Aged; Piperacillin, Tazobactam Drug Combination; Population Surveillance; Saudi Arabia; Tertiary Care Centers; Vancomycin; Young Adult

2018
Perceived differences between intensivists and infectious diseases consultants facing antimicrobial resistance: a global cross-sectional survey.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2019, Volume: 38, Issue:7

    Topics: Anti-Bacterial Agents; Carbapenems; Cohort Studies; Communicable Diseases; Critical Care; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Global Health; Humans; Infection Control; Intensive Care Units; Microbial Sensitivity Tests; Physicians

2019
Oral Fosfomycin-Supplemental Information Necessary.
    Deutsches Arzteblatt international, 2019, 02-15, Volume: 116, Issue:7

    Topics: Anti-Bacterial Agents; Carbapenems; Communicable Diseases; Fosfomycin; Humans

2019
Impact of a program combining pre-authorization requirement and post-prescription review of carbapenems: an interrupted time-series analysis.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2013, Volume: 32, Issue:12

    Topics: Aged; Carbapenems; Communicable Diseases; Drug Utilization; Drug Utilization Review; Female; Humans; Male; Middle Aged; Prescriptions; Prospective Studies; Tertiary Care Centers; Vancomycin

2013
Multidrug-resistant Pseudomonas aeruginosa infections pose growing threat to health care-associated infection control in the hospitals of Southern China: a case-control surveillance study.
    American journal of infection control, 2014, Volume: 42, Issue:12

    Topics: Anti-Bacterial Agents; Carbapenems; Case-Control Studies; China; Communicable Diseases; Cross Infection; Drug Resistance, Multiple, Bacterial; Epidemiological Monitoring; Female; Hospitalization; Hospitals; Humans; Infection Control; Intubation, Intratracheal; Logistic Models; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors

2014
Antimicrobial stewardship for carbapenem use at a Japanese tertiary care center: An interrupted time series analysis on the impact of infectious disease consultation, prospective audit, and feedback.
    American journal of infection control, 2016, 06-01, Volume: 44, Issue:6

    Topics: Anti-Bacterial Agents; Carbapenems; Communicable Diseases; Drug Utilization; Feedback; Humans; Interrupted Time Series Analysis; Organizational Policy; Referral and Consultation; Tertiary Care Centers; Tokyo

2016
Necessity of carbapenem use when prescribed per infectious diseases specialists.
    Diagnostic microbiology and infectious disease, 2017, Volume: 88, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Communicable Diseases; Drug Prescriptions; Drug Utilization; Female; Health Services Research; Humans; Infectious Disease Medicine; Male; Middle Aged; Retrospective Studies; Specialization; Treatment Outcome; Young Adult

2017